Author + information
- Bernardo Cortese1,
- Sameer Dani2,
- Keyur Parikh3,
- Ranjan Shetty4,
- N Prathap Kumar5 and
- Jagdish Hiremath6
Interventions in small coronary vessels (reference vessel diameter ≤2.75 mm) constitute a considerable proportion (30-50%) of greater than 1 million coronary catheter-based procedures performed worldwide each year. We aimed to evaluate the performance of Sirolimus Coated Balloon (SCB) MagicTouchTM in this setting.
156 patients with small vessel treated with Sirolimus Coated Balloon MagicTouchTM modality were enrolled in the Nanolute which was prospective, Multi-center and real world study. The prime endpoints of the study were MACE (Major Cardiac Adverse Event) at 6 and 12 months. MACE was delineated as a composite of Cardiac Death, Target Vessel Myocardial Infarction (TV-MI) and Target Lesion Revascularization (TLR)/Target Vessel Revascularization (TVR).
The cohort was predominated by male patients (81.41%). Risk factors such as diabetes and hypertension were reported in 41.67% and 44.87% patients respectively. Almost half of the patients had a multivessel disease (48.72%). The majority of the lesions were sited in a left anterior descending artery (49.4%). Mean device diameter and length were 2.37 ± 0.31 mm and 21.26 ± 7.04 mm respectively. SCB alone therapy was employed in most of the patients (94.87%) while very few patients (5.13%) underwent additional stenting. 98.08% (153/156) patients completed 6 months follow-up and the reported MACE rate was 2.61%. The incidence of MACE at 12 months was reported as 3.50% in 91.62% (143/156) patients. MACE rate at 12 months was mostly driven by TLR/TVR (2.80%) followed by death (0.70%).
Treatment of coronary stenosis in small coronary vessels with the SCB MagicTouchTM was well tolerated. It may offer an alternative to the implantation of a drug-eluting stent.